» Articles » PMID: 9279880

Metabolism of Azetirelin, a New Thyrotropin-releasing Hormone (TRH) Analogue, by Intestinal Microorganisms

Overview
Journal Pharm Res
Specialties Pharmacology
Pharmacy
Date 1997 Aug 1
PMID 9279880
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: We evaluated the effect of luminal bacterial metabolism on intestinal absorption of azetirelin in rats. In vitro characteristics of bacterial metabolism of azetirelin were also investigated with the goal of overcoming the low stability of the peptidic drug against luminal microorganisms.

Methods: Plasma azetirelin levels after oral administration to antibiotic-pretreated rats was examined. In vitro incubation experiments with bacterial suspensions were also performed to clarify the location of azetirelin breakdown activity as well as the effects of oxygen, pH, and various protease inhibitors on drug metabolism.

Results: Plasma azetirelin levels were sustained after oral administration to antibiotic-treated rats. Incubation with rat luminal contents demonstrated that azetirelin was metabolized by anacrobic bacteria, which are predominant in the distal intestine. Fecal suspensions from rats, dogs, and humans showed comparable metabolic activity. Azetirelin breakdown in the bacterial suspension was pH-dependent and was inhibited in the presence of bacitracin or puromycin.

Conclusions: Bacterial metabolism influences the degree of absorption of azetirelin in the distal intestine. Control of the luminal pH environment may be a practical method for improving the stability of azetirelin against intestinal microorganisms.

Citing Articles

Microbial metabolism marvels: a comprehensive review of microbial drug transformation capabilities.

Martinelli F, Thiele I Gut Microbes. 2024; 16(1):2387400.

PMID: 39150897 PMC: 11332652. DOI: 10.1080/19490976.2024.2387400.


Dissecting the human gut microbiome to better decipher drug liability: A once-forgotten organ takes center stage.

Cai J, Auster A, Cho S, Lai Z J Adv Res. 2023; 52:171-201.

PMID: 37419381 PMC: 10555929. DOI: 10.1016/j.jare.2023.07.002.


How to Determine the Role of the Microbiome in Drug Disposition.

Bisanz J, Spanogiannopoulos P, Pieper L, Bustion A, Turnbaugh P Drug Metab Dispos. 2018; 46(11):1588-1595.

PMID: 30111623 PMC: 7333656. DOI: 10.1124/dmd.118.083402.


Gut microbiome interactions with drug metabolism, efficacy, and toxicity.

Wilson I, Nicholson J Transl Res. 2016; 179:204-222.

PMID: 27591027 PMC: 5718288. DOI: 10.1016/j.trsl.2016.08.002.


Developing a metagenomic view of xenobiotic metabolism.

Haiser H, Turnbaugh P Pharmacol Res. 2012; 69(1):21-31.

PMID: 22902524 PMC: 3526672. DOI: 10.1016/j.phrs.2012.07.009.

References
1.
Browne P, OCuinn G . An evaluation of the role of a pyroglutamyl peptidase, a post-proline cleaving enzyme and a post-proline dipeptidyl amino peptidase, each purified from the soluble fraction of guinea-pig brain, in the degradation of thyroliberin in vitro. Eur J Biochem. 1983; 137(1-2):75-87. DOI: 10.1111/j.1432-1033.1983.tb07797.x. View

2.
TOZAKI H, Emi Y, Horisaka E, Fujita T, Yamamoto A, Muranishi S . Metabolism of peptide drugs by the microorganisms in rat cecal contents. Biol Pharm Bull. 1995; 18(6):929-31. DOI: 10.1248/bpb.18.929. View

3.
SAFFRAN M, Kumar G, Savariar C, Burnham J, Williams F, Neckers D . A new approach to the oral administration of insulin and other peptide drugs. Science. 1986; 233(4768):1081-4. DOI: 10.1126/science.3526553. View

4.
Macfarlane G, Allison C, Gibson S, Cummings J . Contribution of the microflora to proteolysis in the human large intestine. J Appl Bacteriol. 1988; 64(1):37-46. DOI: 10.1111/j.1365-2672.1988.tb02427.x. View

5.
Lindenbaum J, Rund D, Butler Jr V, Saha J . Inactivation of digoxin by the gut flora: reversal by antibiotic therapy. N Engl J Med. 1981; 305(14):789-94. DOI: 10.1056/NEJM198110013051403. View